ADMA vs. SMMT

In the year-to-date period, ADMA achieves a 15.69% return, which is significantly higher than SMMT's 2.07% return. Over the past 10 years, ADMA has outperformed SMMT with an annualized return of 8.63%, while SMMT has yielded a comparatively lower 5.65% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ADMA Sharpe Ratio is 1.64, which is higher than the SMMT Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of ADMA and SMMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ADMA nor SMMT has paid dividends to shareholders.

The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for ADMA and SMMT.

The current volatility for ADMA Biologics, Inc. (ADMA) is 14.61%, while Summit Therapeutics Inc. (SMMT) has a volatility of 43.51%. This indicates that ADMA experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between ADMA Biologics, Inc. and Summit Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.